Developer docs
API playgroundTry for free, no card

Search company profiles

Genuity Science

Full company profile

uuid00046um

Namestring
Genuity Science
Legal namestring
Genuity Science (Ireland) Limited
Websiteurl
genuitysci.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Genuity Science (Ireland) Limited is a privately-funded life sciences company, formerly known as Genomics Medicine Ireland and WuXi NextCODE, wholly owned by US-based biotech HiberCell Inc. The company operates a CAP-accredited genomics laboratory in Cherrywood, Co. Dublin and maintains a registered office in Dun Laoghaire, with operational footprints in the US (Boston) and the UK. It builds and curates disease-specific clinico-omic cohorts — combining whole-genome sequencing, multi-omic data, and longitudinal clinical/phenotypic information — across eight conditions: Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Inflammatory Bowel Disease, Lupus, Heart Failure, Liver Disease, and Diabetic and Non-diabetic Nephropathy. Cohort construction draws on an established network of hospital, academic, and primary-care partners in Ireland, the UK, and the US (including Emory, Vanderbilt, Yale, Cambridge, UMass, USC, and Vanderbilt University Medical Center). All data handling is GDPR-compliant and operates under Irish Data Protection and Health Research regulations, with ISO-certified EU cloud storage.

The company monetizes through multi-year, bespoke commercial research agreements in which pharmaceutical and biotechnology partners receive restricted read-only access to select de-identified datasets and associated analytics. Application areas are organized around four service lines: Target Discovery (genetic-evidence-driven target identification), Portfolio Optimization (candidate target/biomarker validation), Clinical Trials (sub-population identification for study design and enrollment), and Biomarker Discovery (higher-resolution disease stratification). Underlying capabilities include Custom Cohorts, Next Generation Sequencing, and Data Analysis services led by published scientists, supported by what the company describes as the industry's only data analysis platform purpose-built for population-scale genomics and integrating deep learning methods.

The go-to-market is enterprise field sales: named commercial partners include AbbVie (since 2017, the longest-tenured relationship), Vesalius Therapeutics (2022, Parkinson's focus), Ionis Pharmaceuticals (2024, antisense drug development), and Alumis Inc (2026, multi-disease). Cumulative disclosed equity funding totals roughly $455M across rounds in 2013, 2017, and 2018, with the most recent $200M Series 3 led by the Ireland Strategic Investment Fund alongside Sequoia Capital, Temasek, and YF Capital. The company employs 101–250 people and has no public revenue disclosure. Pricing is not publicly disclosed; contracts are individually negotiated.

Short descriptiontext

Genuity Science is a privately-held, Dublin-based clinico-omics data company that builds disease-specific, whole-genome sequencing cohorts enriched with deep phenotypic data and licenses restricted access to pharmaceutical and biotechnology partners for target discovery, biomarker identification, and clinical trial design in CNS, cardiometabolic, and inflammatory diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
population genomics services, clinical genomic data, drug discovery data, multi-omic analysis, biomarker discovery
Industry5 codes
PRIMARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Population Genomics Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Commercial Research Partnerships
TypeSubscription Recurring
Description

Genuity Science provides pharmaceutical and biotechnology companies with restricted read-only access to select de-identified datasets for commercial research purposes. Partners pay for access to data and analysis services through multi-year research agreements.

genuitysci.com
2Genomics Services
TypeProfessional Services
Description

End-to-end genomics services including study design, cohort sourcing, sample preparation, sequencing, and advanced analytics applied to genotypic and phenotypic data for commercial and academic research partners.

genuitysci.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Genuity Science provides population-scale genomics and clinico-omic data products and services to pharmaceutical and biotechnology companies for drug discovery. The company combines retrospective and prospective disease-specific datasets with whole genome sequencing, deep phenotypic data, and multi-omic analysis powered by deep learning methods to support target discovery, biomarker identification, clinical trial design, and portfolio optimization across CNS, cardiometabolic, and inflammatory disease areas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Multi-year partnerships with major pharmaceutical companies (AbbVie since 2017, Vesalius 2022, Ionis 2024) demonstrate commercial validation of platform.
Product overview1 text field

Genuity Science is a life sciences company offering a portfolio of genomics services and disease-specific data products to accelerate drug discovery in CNS, cardiometabolic, and inflammatory diseases. The core offerings include Target Discovery, Portfolio Optimization, Clinical Trials support, and Biomarker Discovery services, all powered by Population Genomics and Population Multi-Omics datasets. Supporting services include Custom Cohorts, Next Generation Sequencing (from their CAP-accredited genomics laboratory), and Data Analysis services led by published scientists. The company provides disease-specific datasets across eight conditions: Alzheimer's, Diabetic and Non-diabetic Nephropathy, Heart Failure, Inflammatory Bowel Disease, Liver Disease, Lupus, Multiple Sclerosis, and Parkinson's. The company is owned by HiberCell Inc. and was previously known as Genomics Medicine Ireland and WuXi NextCODE.

Product and service9 records
1Population Genomics
CategoryPopulation Genomics Data Product
Description

Curated, disease-specific, longitudinal deep phenotyped genomic cohorts in CNS, cardiometabolic, and inflammatory disease areas, powered for statistical significance with whole genome data, sold to pharmaceutical and biotechnology companies for research use.

2Population Multi-Omics
CategoryMulti-Omics Data Product
Description

Focused multi-omic sub-cohorts built from each population genomic cohort, enabling clients to combine genetic evidence with biological function to establish causality and effect for therapeutic discovery.

3Custom Cohorts
CategoryGenomics Service
Description

Custom disease-specific cohort building service providing statistically powered cohorts with whole genome data enriched with deep phenotypic data for longitudinal insight, tailored to client research requirements.

4Next Generation Sequencing
CategoryGenomics Service
Description

Whole genome sequencing service delivered through a CAP-accredited genomics laboratory, providing high-quality, scalable genomic services with world-class expertise and personalized service for research partners.

5Data Analysis
CategoryAnalytics Service
Description

Advanced analytics services for genomic and phenotypic data led by published scientists, covering predictive analytics, process automation, and disease-progression modeling on population-scale datasets.

6Target Discovery
CategoryDrug Discovery Service
Description

Service that identifies novel therapeutic targets with strong genetic evidence to support drug discovery programs in CNS, cardiometabolic, and inflammatory diseases, using the company's clinico-omic datasets.

7Portfolio Optimization
CategoryDrug Discovery Service
Description

Service that validates candidate drug targets and biomarkers to help pharmaceutical clients focus R&D investment, leveraging Genuity Science's disease-specific clinico-omic datasets.

8Clinical Trials Support
CategoryClinical Trial Service
Description

Service that supports clinical trial design by identifying relevant patient sub-populations and informing enrollment criteria using the company's genomic and phenotypic datasets.

9Biomarker Discovery
CategoryBiomarker Discovery Service
Description

Service that discovers novel biomarkers enabling higher resolution disease stratification for improved patient targeting and therapeutic outcomes in CNS, cardiometabolic, and inflammatory diseases.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Alumis Inc
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Genuity Science began a project with Alumis Inc in 2026. The goal is to bring together comprehensive datasets including multiple disease areas to enable better understanding of drivers of disease and therapeutic response, with the aim of optimising therapeutic outcomes for patients.

genuitysci.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Genuity Science began a multi-year agreement in 2024 with Ionis Pharmaceuticals. The goal is to bring together a comprehensive database to enable better understanding of disease mechanisms which, combined with Ionis' proprietary antisense technology, has the potential to significantly expedite drug development through more direct translation of targets into therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Genuity Science began a multi-year agreement in 2022 with Vesalius Therapeutics. The goal is to bring together a comprehensive database to enable evaluation of variability among patients with Parkinson's disease to better understand disease severity and symptoms. Designed to facilitate identification of more refined patient subpopulations for advancement of specific therapeutic agents in specific patient subpopulations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Genuity Science (then Genomics Medicine Ireland and WuXi NextCODE) commenced a partnership with AbbVie in 2017. As part of the collaboration, Genuity Science conducts population genomics research aimed at advancing the discovery of novel therapeutic approaches to major chronic diseases. This is the company's longest-standing commercial partnership.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partnership for population genomics research collaboration.

6Nashville Biosciences
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partnership for population genomics research collaboration.

genuitysci.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partnership for population genomics research collaboration based in the UK.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partnership for population genomics research collaboration.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partnership for population genomics research collaboration.

10Vanderbilt University Medical Center
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partnership for population genomics research collaboration.

genuitysci.com
11Yale University Medical Center
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partnership for population genomics research collaboration.

genuitysci.com
Strategic tierFlagshipTypeOthers
Description

Genuity Science (Ireland) Limited is owned by HiberCell Inc., a US-based biotech company. HiberCell is the parent company of Genuity Science.

13Hospital, Academic and Clinical Research Centers (Ireland)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Network of Irish healthcare and research institutions providing clinical sites for population genomics studies and cohort recruitment.

genuitysci.com
14Primary Care Centers (UK)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

UK-based primary care centres participating in population genomics research collaborations.

genuitysci.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Roche-owned molecular genomics profiling company serving oncology drug development; comparable in pharma partnership model and genomic data licensing, though focused on oncology rather than CNS/cardiometabolic/inflammatory.

TypeBroad incumbent
Description

Large-scale public population genomics and health database with 500,000+ participants; serves as both a substitute (free academic access) and complement (validation cohort) to commercial population genomics providers.

TypeBroad incumbent
Description

Alphabet-subsidiary precision health platform operating population-scale studies (e.g., Project Baseline) combining genomics, multi-omics, and clinical data — comparable in scale and pharma partnership model.

4Tempus Labs
TypeEmerging player
Description

AI-enabled precision medicine company with multi-modal (DNA, RNA, imaging, clinical) data library licensed to pharma; comparable data-licensing business model with broader therapeutic coverage including oncology and neuropsychiatry.

TypeDirect peer
Description

Amgen-owned population genomics platform focused on disease gene discovery using large-scale WGS and deep phenotypic data from the Icelandic population — directly comparable business model and disease-cohort focus.

TypeDirect peer
Description

Combines whole-genome sequencing, multi-omic profiling, and AI-driven analysis to build a comprehensive health database — comparable technology stack and target customer base in pharma and preventive health.

TypeDirect peer
Description

Population genomics and clinical genomic sequencing platform partnering with health systems and pharma; offers similar CAP-accredited sequencing and population-scale data assets for research and clinical applications.

TypeDirect peer
Description

Consumer-genomics platform with a therapeutics arm that licenses population genomic data and targets to pharma — comparable in monetizing population-scale genetic data for drug discovery.

9Bristol Myers Squibb (Celgene) Genetic Analysis Platform
TypeOthers
Description

Large pharma with internal population genomics programs that compete for pharma R&D budget allocation; relevant as both potential customer and competitor building similar in-house capabilities.

TypeDirect peer
Description

Operates one of the world's largest human genetics databases linked to electronic health records; partners with pharma for target discovery and validation — directly comparable data-platform-as-a-service model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment5 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genuity Science

Population Genomics Servicesgenuitysci.com

Genuity Science is a privately-held, Dublin-based clinico-omics data company that builds disease-specific, whole-genome sequencing cohorts enriched with deep phenotypic data and licenses restricted access to pharmaceutical and biotechnology partners for target discovery, biomarker identification, and clinical trial design in CNS, cardiometabolic, and inflammatory diseases.

What Genuity Science does

Genuity Science (Ireland) Limited is a privately-funded life sciences company, formerly known as Genomics Medicine Ireland and WuXi NextCODE, wholly owned by US-based biotech HiberCell Inc. The company operates a CAP-accredited genomics laboratory in Cherrywood, Co. Dublin and maintains a registered office in Dun Laoghaire, with operational footprints in the US (Boston) and the UK. It builds and curates disease-specific clinico-omic cohorts — combining whole-genome sequencing, multi-omic data, and longitudinal clinical/phenotypic information — across eight conditions: Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Inflammatory Bowel Disease, Lupus, Heart Failure, Liver Disease, and Diabetic and Non-diabetic Nephropathy. Cohort construction draws on an established network of hospital, academic, and primary-care partners in Ireland, the UK, and the US (including Emory, Vanderbilt, Yale, Cambridge, UMass, USC, and Vanderbilt University Medical Center). All data handling is GDPR-compliant and operates under Irish Data Protection and Health Research regulations, with ISO-certified EU cloud storage.

The company monetizes through multi-year, bespoke commercial research agreements in which pharmaceutical and biotechnology partners receive restricted read-only access to select de-identified datasets and associated analytics. Application areas are organized around four service lines: Target Discovery (genetic-evidence-driven target identification), Portfolio Optimization (candidate target/biomarker validation), Clinical Trials (sub-population identification for study design and enrollment), and Biomarker Discovery (higher-resolution disease stratification). Underlying capabilities include Custom Cohorts, Next Generation Sequencing, and Data Analysis services led by published scientists, supported by what the company describes as the industry's only data analysis platform purpose-built for population-scale genomics and integrating deep learning methods.

The go-to-market is enterprise field sales: named commercial partners include AbbVie (since 2017, the longest-tenured relationship), Vesalius Therapeutics (2022, Parkinson's focus), Ionis Pharmaceuticals (2024, antisense drug development), and Alumis Inc (2026, multi-disease). Cumulative disclosed equity funding totals roughly $455M across rounds in 2013, 2017, and 2018, with the most recent $200M Series 3 led by the Ireland Strategic Investment Fund alongside Sequoia Capital, Temasek, and YF Capital. The company employs 101–250 people and has no public revenue disclosure. Pricing is not publicly disclosed; contracts are individually negotiated.

Genuity Science firmographics

Firmographics
Name
Genuity Science
Legal name
Genuity Science (Ireland) Limited
Website
https://genuitysci.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Genuity Science is a privately-held, Dublin-based clinico-omics data company that builds disease-specific, whole-genome sequencing cohorts enriched with deep phenotypic data and licenses restricted access to pharmaceutical and biotechnology partners for target discovery, biomarker identification, and clinical trial design in CNS, cardiometabolic, and inflammatory diseases.
Ownership category
akta.pro rank

Genuity Science industry classification

Industry
Product category
Population Genomics Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Population genomics services
  • Clinical genomic data
  • Drug discovery data
  • Multi-omic analysis
  • Biomarker discovery

Where Genuity Science is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Genuity Science business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Commercial Research Partnerships: Genuity Science provides pharmaceutical and biotechnology companies with restricted read-only access to select de-identified datasets for commercial research purposes. Partners pay for access to data and analysis services through multi-year research agreements.
  2. Genomics Services: End-to-end genomics services including study design, cohort sourcing, sample preparation, sequencing, and advanced analytics applied to genotypic and phenotypic data for commercial and academic research partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Genuity Science product offering

Product offering

Core offering

Genuity Science provides population-scale genomics and clinico-omic data products and services to pharmaceutical and biotechnology companies for drug discovery. The company combines retrospective and prospective disease-specific datasets with whole genome sequencing, deep phenotypic data, and multi-omic analysis powered by deep learning methods to support target discovery, biomarker identification, clinical trial design, and portfolio optimization across CNS, cardiometabolic, and inflammatory disease areas.

Product overview

Genuity Science is a life sciences company offering a portfolio of genomics services and disease-specific data products to accelerate drug discovery in CNS, cardiometabolic, and inflammatory diseases. The core offerings include Target Discovery, Portfolio Optimization, Clinical Trials support, and Biomarker Discovery services, all powered by Population Genomics and Population Multi-Omics datasets. Supporting services include Custom Cohorts, Next Generation Sequencing (from their CAP-accredited genomics laboratory), and Data Analysis services led by published scientists. The company provides disease-specific datasets across eight conditions: Alzheimer's, Diabetic and Non-diabetic Nephropathy, Heart Failure, Inflammatory Bowel Disease, Liver Disease, Lupus, Multiple Sclerosis, and Parkinson's. The company is owned by HiberCell Inc. and was previously known as Genomics Medicine Ireland and WuXi NextCODE.

Differentiator

Problem solved

Functional benefit

Products and services

  • Population Genomics Curated, disease-specific, longitudinal deep phenotyped genomic cohorts in CNS, cardiometabolic, and inflammatory disease areas, powered for statistical significance with whole genome data, sold to pharmaceutical and biotechnology companies for research use.
  • Population Multi-Omics Focused multi-omic sub-cohorts built from each population genomic cohort, enabling clients to combine genetic evidence with biological function to establish causality and effect for therapeutic discovery.
  • Custom Cohorts Custom disease-specific cohort building service providing statistically powered cohorts with whole genome data enriched with deep phenotypic data for longitudinal insight, tailored to client research requirements.
  • Next Generation Sequencing Whole genome sequencing service delivered through a CAP-accredited genomics laboratory, providing high-quality, scalable genomic services with world-class expertise and personalized service for research partners.
  • Data Analysis Advanced analytics services for genomic and phenotypic data led by published scientists, covering predictive analytics, process automation, and disease-progression modeling on population-scale datasets.
  • Target Discovery Service that identifies novel therapeutic targets with strong genetic evidence to support drug discovery programs in CNS, cardiometabolic, and inflammatory diseases, using the company's clinico-omic datasets.
  • Portfolio Optimization Service that validates candidate drug targets and biomarkers to help pharmaceutical clients focus R&D investment, leveraging Genuity Science's disease-specific clinico-omic datasets.
  • Clinical Trials Support Service that supports clinical trial design by identifying relevant patient sub-populations and informing enrollment criteria using the company's genomic and phenotypic datasets.
  • Biomarker Discovery Service that discovers novel biomarkers enabling higher resolution disease stratification for improved patient targeting and therapeutic outcomes in CNS, cardiometabolic, and inflammatory diseases.

Quantifiable outcome

  • Multi-year partnerships with major pharmaceutical companies (AbbVie since 2017, Vesalius 2022, Ionis 2024) demonstrate commercial validation of platform.

Companies that use Genuity Science

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Genuity Science technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Genuity Science partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core, supporting and flagship.

  • Alumis InccoreStrategic or Co-development Partner · 1 January 2026Genuity Science began a project with Alumis Inc in 2026. The goal is to bring together comprehensive datasets including multiple disease areas to enable better understanding of drivers of disease and therapeutic response, with the aim of optimising therapeutic outcomes for patients.
  • Ionis PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2024Genuity Science began a multi-year agreement in 2024 with Ionis Pharmaceuticals. The goal is to bring together a comprehensive database to enable better understanding of disease mechanisms which, combined with Ionis' proprietary antisense technology, has the potential to significantly expedite drug development through more direct translation of targets into therapies.
  • Vesalius TherapeuticscoreStrategic or Co-development Partner · 1 January 2022Genuity Science began a multi-year agreement in 2022 with Vesalius Therapeutics. The goal is to bring together a comprehensive database to enable evaluation of variability among patients with Parkinson's disease to better understand disease severity and symptoms. Designed to facilitate identification of more refined patient subpopulations for advancement of specific therapeutic agents in specific patient subpopulations.
  • AbbViecoreStrategic or Co-development Partner · 1 January 2017Genuity Science (then Genomics Medicine Ireland and WuXi NextCODE) commenced a partnership with AbbVie in 2017. As part of the collaboration, Genuity Science conducts population genomics research aimed at advancing the discovery of novel therapeutic approaches to major chronic diseases. This is the company's longest-standing commercial partnership.
  • Emory UniversitysupportingStrategic or Co-development PartnerAcademic research partnership for population genomics research collaboration.
  • Nashville BiosciencessupportingStrategic or Co-development PartnerAcademic research partnership for population genomics research collaboration.
  • University of CambridgesupportingStrategic or Co-development PartnerAcademic research partnership for population genomics research collaboration based in the UK.
  • University of Massachusetts Medical CentersupportingStrategic or Co-development PartnerAcademic research partnership for population genomics research collaboration.
  • University of Southern CaliforniasupportingStrategic or Co-development PartnerAcademic research partnership for population genomics research collaboration.
  • Vanderbilt University Medical CentersupportingStrategic or Co-development PartnerAcademic research partnership for population genomics research collaboration.
  • Yale University Medical CentersupportingStrategic or Co-development PartnerAcademic research partnership for population genomics research collaboration.
  • HiberCell Inc.flagshipOthersGenuity Science (Ireland) Limited is owned by HiberCell Inc., a US-based biotech company. HiberCell is the parent company of Genuity Science.
  • Hospital, Academic and Clinical Research Centers (Ireland)supportingStrategic or Co-development PartnerNetwork of Irish healthcare and research institutions providing clinical sites for population genomics studies and cohort recruitment.
  • Primary Care Centers (UK)supportingStrategic or Co-development PartnerUK-based primary care centres participating in population genomics research collaborations.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Genuity Science competitors and assessment

Company assessment

Broad incumbents

  • Foundation Medicine: Roche-owned molecular genomics profiling company serving oncology drug development; comparable in pharma partnership model and genomic data licensing, though focused on oncology rather than CNS/cardiometabolic/inflammatory.
  • UK Biobank: Large-scale public population genomics and health database with 500,000+ participants; serves as both a substitute (free academic access) and complement (validation cohort) to commercial population genomics providers.
  • Verily Life Sciences: Alphabet-subsidiary precision health platform operating population-scale studies (e.g., Project Baseline) combining genomics, multi-omics, and clinical data — comparable in scale and pharma partnership model.

Emerging players

  • Tempus Labs: AI-enabled precision medicine company with multi-modal (DNA, RNA, imaging, clinical) data library licensed to pharma; comparable data-licensing business model with broader therapeutic coverage including oncology and neuropsychiatry.

Direct peers

  • deCODE Genetics: Amgen-owned population genomics platform focused on disease gene discovery using large-scale WGS and deep phenotypic data from the Icelandic population — directly comparable business model and disease-cohort focus.
  • Human Longevity Inc. Combines whole-genome sequencing, multi-omic profiling, and AI-driven analysis to build a comprehensive health database — comparable technology stack and target customer base in pharma and preventive health.
  • Helix: Population genomics and clinical genomic sequencing platform partnering with health systems and pharma; offers similar CAP-accredited sequencing and population-scale data assets for research and clinical applications.
  • 23andMe Therapeutics: Consumer-genomics platform with a therapeutics arm that licenses population genomic data and targets to pharma — comparable in monetizing population-scale genetic data for drug discovery.
  • Regeneron Genetics Center: Operates one of the world's largest human genetics databases linked to electronic health records; partners with pharma for target discovery and validation — directly comparable data-platform-as-a-service model.

Others

  • Bristol Myers Squibb (Celgene) Genetic Analysis Platform: Large pharma with internal population genomics programs that compete for pharma R&D budget allocation; relevant as both potential customer and competitor building similar in-house capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Genuity Science social profiles

Digital presence

Genuity Science compliance and trust

Trust signal

Compliance2 records

Genuity Science financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genuity Science leadership team

Management profile

Number of profiles

Profiles5 records

Genuity Science funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genuity Science M&A and investment

M&A and investment

M&A1 record

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genuity Science

What does Genuity Science do?

Genuity Science provides population-scale genomics and clinico-omic data products and services to pharmaceutical and biotechnology companies for drug discovery. The company combines retrospective and prospective disease-specific datasets with whole genome sequencing, deep phenotypic data, and multi-omic analysis powered by deep learning methods to support target discovery, biomarker identification, clinical trial design, and portfolio optimization across CNS, cardiometabolic, and inflammatory disease areas.

Is Genuity Science a public or private company?

Genuity Science is a private company. It is classified as corporate owned and is currently operating.

When was Genuity Science founded?

Genuity Science was founded in 2013. It employs 11 to 50 people.

Where is Genuity Science based?

Genuity Science is headquartered in Boston, United States, in the North America region.

How does Genuity Science make money?

Two revenue lines are on record. Commercial Research Partnerships are the primary driver. The others are genomics Services.

Who are Genuity Science's main competitors?

Broad incumbents on record are Foundation Medicine, UK Biobank and Verily Life Sciences. Tempus Labs is listed as an emerging player. Direct peers are deCODE Genetics, Human Longevity Inc., Helix, 23andMe Therapeutics and Regeneron Genetics Center. Bristol Myers Squibb (Celgene) Genetic Analysis Platform is listed as an others.

Does Genuity Science have an API?

No public API is recorded for Genuity Science.

What industry is Genuity Science in?

Genuity Science's product category is Population Genomics Services. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAAANAL, Population Genomics & Preventive Precision Health Programs. Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Irish TimesCompany selling DNA data boosts profits to nearly €5m as it scales back Irish operationsGenuity Science Ireland reported pretax profits of €4.88 million in 2025, up 24% from 2024, with revenue of $6.87 million, up 17.73%. The Dublin-based firm, owned by HiberCell, is scaling back operations and has no R&D expenses.AbbvieOur ApproachAbbVie is investing in research and fostering partnerships to discover products addressing patients' health needs, emphasizing collaborative R&D agreements. The company has engaged in specific initiatives such as a 15-year genomic research alliance with Genuity Science in Ireland and a joint investment with the Department of Jobs, Enterprise, and Innovation through Science Foundation Ireland.The Irish TimesFuture of Genuity’s Irish DNA database is worryingly uncertainThe future of Genuity Science Ireland's genomic database is uncertain following financial losses that threaten its funding from parent company HiberCell. The article highlights concerns over the use of taxpayer funds and controversial consent mechanisms for collecting DNA samples, with critics calling for the data to be transferred to a new public infrastructure project. Meanwhile, the Irish government has launched Genomics Data Infrastructure (GDI) Ireland to establish secure national standards for managing genetic data.RTE.ieDNA analysis firm Genuity Science bought by HiberCellHiberCell acquired DNA analysis firm Genuity Science in an all-stock deal, giving HiberCell about $100 million in cash and Genuity's partnerships with Ionis and AbbVie. The combined company will use Genuity's AI/ML platform to accelerate its cancer drug pipeline. Ireland Strategic Investment Fund will become a shareholder.BioSpaceHiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.HiberCell acquired Genuity Science, a genomics and multi-omic analytics company, for approximately $100 million in cash plus existing partnership agreements with Ionis and AbbVie. The acquisition adds AI/ML tools to HiberCell's translational oncology pipeline, with new executive hires including a CTO and CISO.GlobeNewswireHiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.HiberCell acquired Genuity Science, a genomics and multi-omic analytics company, for approximately $100 million in cash and existing partnership agreements with Ionis and AbbVie. The acquisition adds AI/ML tools to HiberCell's translational oncology pipeline, with new executive hires including a CTO and CISO.GlobeNewswireHiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.HiberCell acquired Genuity Science, a genomics and AI/ML analytics company, for approximately $100 million in cash plus existing partnership agreements with Ionis and AbbVie. The acquisition adds Genuity's human genomics and multi-omic datasets to HiberCell's translational oncology pipeline. Future earnouts from the partnerships are expected to support growth.PR NewswireGenuity Science Awarded Designation as a 10x Genomics Certified Service Provider in Single Cell Immune ProfilingGenuity Science, a genomics data and analytics organization, announced its designation as a 10x Genomics Certified Service Provider (CSP) for Single Cell Immune Profiling, making its CAP-accredited laboratory in Dublin, Ireland one of only three European organizations to receive this certification. The partnership enables Genuity Science to support global biopharma customers in leveraging 10x's single-cell technologies for biomarker discovery and therapeutic development. Jeff Gulcher, Chief Scientific Officer at Genuity Science, noted that the collaboration will provide partners with insights to advance understanding of human disease and accelerate therapeutic development.Silicon RepublicComputational statistics at Genuity Science: Where mathematical rigour meets biologyRichard Li, a senior computational statistician at Genuity Science, describes his work applying machine learning and deep learning to genomics data. He recently completed a quantum machine learning project on cancer classification, published in Patterns, and works on projects involving Covid-19 and brain ageing. He emphasizes the need for both biological understanding and mathematical rigour as data generation increases.PR NewswirePatterns Paper Shows Benefits of Modeling Complicated Small Datasets Using Unconventional, Quantum Computing-inspired AlgorithmsGenuity Science, a genomics data organization headquartered in Boston, announced on April 28, 2021 that its paper "Quantum processor-inspired machine learning in the biomedical sciences" was published in the Cell Press journal Patterns. The paper demonstrates that Ising-type algorithms, inspired by quantum computing processors, show competitive or superior performance compared to conventional machine learning algorithms when classifying human cancer types, particularly when working with small, complex datasets. The research suggests potential applications for rare diseases and clinical trials where large datasets may be prohibitively expensive to obtain.